COVID-19 and systemic anti-cancer therapy

doi:10.19401/j.cnki.1007-3639.2022.06.004

Abstract

Abstract:

The corona virus disease 2019 (COVID-19) pandemic continues to severely impact healthcare systems around the world, and patients with cancer are even worse affected owing to compromised immune status and greater exposure risk. In the present review, we retrieved the relevant literature including guidelines and consensuses directly related to the purpose of this study from the PubMed database, and then summarized the research data on cancer and COVID-19, aiming to discuss the personal protection, systemic anti-cancer therapy, outcome of co-infection, and the clinical management strategy in this population. We found that patients with malignant tumors had a higher chance of suffering COVID-19, co-infection of whom had an even worse clinical prognosis, especially for those with lung cancer or hematologic cancers. Systemic chemotherapy may delay the clearance of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) virus of human body, and thus have a negative impact on the clinical outcomes of COVID-19, while certain endocrine therapy and targeted drugs having limited or no impact. There has been no sufficient evidence for the impact of immune checkpoint therapy on the outcomes of COVID-19 till now. It is of great value to strengthen the personal protection of patients, adjust the anti-tumor treatments rationally and optimize the clinical management processes.

Key words: COVID-19, Malignant tumors, Chemotherapy, Anti-tumor therapy, Clinical outcome

CLC Number:

R730.53

HU Xichun, HU Zhihuang, WANG Biyun, WANG Jialei, TAO Rong, ZHANG Jian, GUO Weijian, CHEN Jie, LUO Zhiguo, LI Ting, HUANG Mingzhu, QIU Lixin, SANG Youzhou. COVID-19 and systemic anti-cancer therapy[J]. China Oncology, 2022, 32(6): 499-511.

References 65

[1]	国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL][2022-04-20]http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml, 2022.
	General Office of the National Health Commission, Office of the State Administration of Traditional Chinese Medicine.Diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9)[EB/OL][2022-04-20].>http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml, 2022.
[2]	ZENG C,, EVANS J P,, REISINGER S, et al.Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients[J]. Cell Biosci, 2021, 11(1): 197. doi: 10.1186/s13578-021-00713-2
[3]	PASSAMONTI F,, CATTANEO C,, ARCAINI L, et al.Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study[J]. Lancet Haematol, 2020, 7(10): e737-e745.
[4]	VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al.Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267. doi: 10.1038/s41467-020-20568-4
[5]	GOUBET A G,, DUBUISSON A,, GERAUD A, et al.Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis[J]. Cell Death Differ, 2021, 28(12): 3297-3315. doi: 10.1038/s41418-021-00817-9
[6]	ROGADO J,, GULLÓN P,, OBISPO B, et al.Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors[J]. Eur J Cancer, 2021, 148: 58-60. doi: 10.1016/j.ejca.2021.02.011
[7]	BABADY N E,, COHEN B,, MCCLURE T, et al.Variable duration of viral shedding in cancer patients with coronavirus disease 2019 (COVID-19)[J]. Infect Control Hosp Epidemiol, 2021: 1-3.
[8]	AYDILLO T,, GONZALEZ-REICHE A S,, ASLAM S, et al.Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer[J]. N Engl J Med, 2020, 383(26): 2586-2588. doi: 10.1056/NEJMc2031670
[9]	GOYAL A,, CARDOZO-OJEDA E F,, SCHIFFER J T.Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response[J]. Sci Adv, 2020, 6(47): eabc7112.
[10]	LIU B,, HAN J Y,, CHENG X H, et al.Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients[J]. Sci Rep, 2020, 10(1): 17718. doi: 10.1038/s41598-020-73955-8
[11]	HAMMOND J,, LEISTER-TEBBE H,, GARDNER A, et al.Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19[J]. N Engl J Med, 2022, 386(15): 1397-1408. doi: 10.1056/NEJMoa2118542
[12]	NCCN.Management of covid-19 infection in patients with cancer[EB/OL]. https://www.nccn.org/docs/default-source/covid-19/2021-covid-infectious-disease-management.pdf?sfvrsn=63f70c30_7, 2021.
[13]	LIU Y,, YAN L M,, WAN L G, et al.Viral dynamics in mild and severe cases of COVID-19[J]. Lancet Infect Dis, 2020, 20(6): 656-657. doi: 10.1016/S1473-3099(20)30232-2
[14]	JACOB A S,, KAUL H,, FUCHS M, et al.Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma[J]. Infection, 2022: 1-8.
[15]	LIANG W H,, GUAN W J,, CHEN R C, et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337. doi: 10.1016/S1470-2045(20)30096-6
[16]	AYHAN M,, LAÇIN Ş,, ÖZYÜKSELER D T, et al.Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?[J]. J Oncol Pharm Pract, 2021, 27(6): 1461-1467. doi: 10.1177/10781552211015762
[17]	JEE J,, FOOTE M B,, LUMISH M, et al.Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546. doi: 10.1200/JCO.20.01307
[18]	LEE A J X,, PURSHOUSE K.COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic[J]. Br J Cancer, 2021, 124(11): 1777-1784. doi: 10.1038/s41416-021-01324-x
[19]	COELHO D B,, SANTOS V,, ARAÚJO D, et al.Management of coronavirus disease 2019 patients with lung cancer: experience from a thoracic oncology center[J]. Front Mol Biosci, 2021, 8: 639676. doi: 10.3389/fmolb.2021.639676
[20]	SUTANDYO N,, JAYUSMAN A M,, WIDJAJA L, et al.Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia[J]. Eur Rev Med Pharmacol Sci, 2021, 25(10): 3868-3878.
[21]	LUO J,, RIZVI H,, PREESHAGUL I R, et al.COVID-19 in patients with lung cancer[J]. Ann Oncol, 2020, 31(10): 1386-1396. doi: 10.1016/j.annonc.2020.06.007
[22]	PASSARO A,, BESTVINA C,, VELEZ VELEZ M, et al.Severity of COVID-19 in patients with lung cancer: evidence and challenges[J]. J Immunother Cancer, 2021, 9(3): e002266.
[23]	VÁRNAI C,, PALLES C,, ARNOLD R, et al.Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19[J]. JAMA Netw Open, 2022, 5(2): e220130.
[24]	GARASSINO M C,, WHISENANT J G,, HUANG L C, et al.COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study[J]. Lancet Oncol, 2020, 21(7): 914-922. doi: 10.1016/S1470-2045(20)30314-4
[25]	PROVENCIO M,, MAZARICO GALLEGO J M,, CALLES A, et al.Lung cancer patients with COVID-19 in Spain: GRAVID study[J]. Lung Cancer, 2021, 157: 109-115. doi: 10.1016/j.lungcan.2021.05.014
[26]	HAINEALA B,, ZGURA A,, BADIU D C, et al.Lung cancer, covid-19 infections and chemotherapy[J]. In Vivo, 2021, 35(3): 1877-1880. doi: 10.21873/invivo.12450
[27]	TRIFANESCU O G,, GALES L,, BACINSCHI X, et al.Impact of the COVID-19 pandemic on treatment and oncologic outcomes for cancer patients in Romania[J]. In Vivo, 2022, 36(2): 934-941. doi: 10.21873/invivo.12783
[28]	WU Q,, LUO S M,, XIE X H.The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: A meta-analysis based on 52 cohorts incorporating 9 231 participants[J]. BMC Cancer, 2022, 22(1): 241. doi: 10.1186/s12885-022-09320-x
[29]	HERMEL D J,, CHAM J,, SPIERLING BAGSIC S R, et al.An observational study of hospitalized COVID-19 patients with cancer in San Diego County[J]. Future Oncol, 2022, 18(6): 719-725. doi: 10.2217/fon-2021-1116
[30]	YANG K Y,, SHENG Y H,, HUANG C L, et al.Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study[J]. Lancet Oncol, 2020, 21(7): 904-913. doi: 10.1016/S1470-2045(20)30310-7
[31]	AYHAN M,, LAÇIN Ş,, ÖZYÜKSELER D T, et al.Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?[J]. J Oncol Pharm Pract, 2021, 27(6): 1461-1467. doi: 10.1177/10781552211015762
[32]	MANDALA M,, LORIGAN P,, DE LUCA M, et al.SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study[J]. J Immunother Cancer, 2021, 9(2): e001694.
[33]	PASSARO A,, ADDEO A,, VON GARNIER C, et al.ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000820.
[34]	GARASSINO M C,, WHISENANT J G,, HUANG L C, et al.COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study[J]. Lancet Oncol, 2020, 21(7): 914-922. doi: 10.1016/S1470-2045(20)30314-4
[35]	SO M,, KABATA H,, FUKUNAGA K, et al.Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis[J]. BMC Pulm Med, 2021, 21(1): 97. doi: 10.1186/s12890-021-01463-0
[36]	PINATO D J,, ZAMBELLI A,, AGUILAR-COMPANY J, et al.Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients[J]. Cancer Discov, 2020: CD-20-0773.
[37]	VUAGNAT P,, FRELAUT M,, RAMTOHUL T, et al.COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area[J]. Breast Cancer Res, 2020, 22(1): 55. doi: 10.1186/s13058-020-01293-8
[38]	WEI J L,, WU M J,, LIU J, et al.Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109. doi: 10.1016/j.breast.2021.06.006
[39]	ZHOU Y D,, HOU Y,, SHEN J Y, et al.Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2[J]. Cell Discov, 2020, 6: 14. doi: 10.1038/s41421-020-0153-3
[40]	MARTIN W R,, CHENG F X.Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2[J]. J Proteome Res, 2020, 19(11): 4670-4677. doi: 10.1021/acs.jproteome.0c00397
[41]	ZU S L,, LUO D,, LI L L, et al.Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry[J]. Signal Transduct Target Ther, 2021, 6(1): 435. doi: 10.1038/s41392-021-00853-4
[42]	HU S Y,, YIN F Y,, NIE L T, et al.Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879. doi: 10.3389/fendo.2022.829879
[43]	OTTAVIANO M,, CURVIETTO M,, RESCIGNO P, et al.Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists[J]. J Immunother Cancer, 2020, 8(2): e001154.
[44]	Recommendations for prioritization,treatment and triage of breast cancer patients during the covid-19 pandemic［EB/OL］.American College of Surgeons Available at https://www.facs.org/qualityprograms/cancer/executive-summary. Accessed March 26, 2020.
[45]	DE AZAMBUJA E,, TRAPANI D,, LOIBL S, et al.ESMO Management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
[46]	PINATO D J,, TABERNERO J,, BOWER M, et al.Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study[J]. Lancet Oncol, 2021, 22(12): 1669-1680. doi: 10.1016/S1470-2045(21)00573-8
[47]	ZHANG H Y,, WANG L W,, CHEN Y Y, et al.Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China[J]. Cancer, 2020, 126(17): 4023-4031. doi: 10.1002/cncr.33042
[48]	LEE L Y W,, CAZIER J B,, STARKEY T, et al.COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study[J]. Lancet Oncol, 2020, 21(10): 1309-1316. doi: 10.1016/S1470-2045(20)30442-3
[49]	LIU H Q,, YANG D,, CHEN X Y, et al.The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis[J]. Cancer Med, 2021, 10(3): 1043-1056. doi: 10.1002/cam4.3692
[50]	VÁRNAI C,, PALLES C,, ARNOLD R, et al.Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19[J]. JAMA Netw Open, 2022, 5(2): e220130.
[51]	MUKHERJI R,, MARSHALL J L.Lessons learned in managing patients with colorectal cancer during the COVID-19 pandemic[J]. Curr Treat Options Oncol, 2021, 22(10): 93. doi: 10.1007/s11864-021-00888-3
[52]	GARCÍA-SUÁREZ J,, DE LA CRUZ J,, CEDILLO Á, et al.Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study[J]. J Hematol Oncol, 2020, 13(1): 133. doi: 10.1186/s13045-020-00970-7
[53]	DULÉRY R,, LAMURE S,, DELORD M, et al.Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy[J]. Am J Hematol, 2021, 96(8): 934-944. doi: 10.1002/ajh.26209
[54]	GHIONE P,, GU J J,, ATTWOOD K, et al.Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies[J]. Blood, 2021, 138(9): 811-814.
[55]	TREON S P,, CASTILLO J J,, SKARBNIK A P, et al.he BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020; 135(21): 1912-1915[J].Blood, 2021, 137(11): 1561. doi: 10.1182/blood.2021010938
[56]	SCARFÒ L,, CHATZIKONSTANTINOU T,, RIGOLIN G M, et al.COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus[J]. Leukemia, 2020, 34(9): 2354-2363. doi: 10.1038/s41375-020-0959-x
[57]	GIESEN N,, SPRUTE R,, RÜTHRICH M, et al.2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy[J]. Eur J Cancer, 2021, 147: 154-160. doi: 10.1016/j.ejca.2021.01.033
[58]	LEE L Y,, CAZIER J B,, ANGELIS V, et al.COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926. doi: 10.1016/S0140-6736(20)31173-9
[59]	KUDERER N M,, CHOUEIRI T K,, SHAH D P, et al.Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study[J]. Lancet, 2020, 395(10241): 1907-1918. doi: 10.1016/S0140-6736(20)31187-9
[60]	SATHIAN B,, ASIM M,, BANERJEE I, et al.Impact of COVID-19 on clinical trials and clinical research: a systematic review[J]. Nepal J Epidemiol, 2020, 10(3): 878-887. doi: 10.3126/nje.v10i3.31622
[61]	DE PAULA B H R,, ARAÚJO I,, BANDEIRA L, et al.Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic[J]. Lancet Oncol, 2020, 21(5): 624-627. doi: 10.1016/S1470-2045(20)30226-6
[62]	李丹,, 刘晓红,, 卢冬青, 等.新型冠状病毒肺炎疫情下抗肿瘤药物临床试验受试者的随访分析[J]. 中国新药杂志, 2021, 30(12): 1099-1102.
	LI D,, LIU X H,, LU D Q, et al.Analysis of follow-up for subjects of anti-cancer clinical trials under COVID-19[J]. Chin J New Drugs, 2021, 30(12): 1099-1102.
[63]	刘小保,, 高素彬,, 衡建福, 等.新冠肺炎疫情下抗肿瘤药物临床试验现状与紧急应对策略[J]. 肿瘤药学, 2020, 10(S1): 2-10.
	LIU X B,, GAO S B,, HENG J F, et al.The Current situation of anti-cancer drug clinical trial during the epidemic of COVID-19 and the emergency response strategies[J]. Anti Tumor Pharm, 2020, 10(S1): 2-10.
[64]	刘丹,, 曾圣雅,, 邓璠, 等.临床科研项目知情同意过程存在问题及解决途径[J]. 中国医学伦理学, 2018, 31(6): 732-735.
	LIU D,, ZENG S Y,, DENG F, et al.Existing problems and solution of informed consent in clinical research[J]. Chin Med Ethics, 2018, 31(6): 732-735.
[65]	GIESEN N,, SPRUTE R,, RÜTHRICH M, et al.2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy[J]. Eur J Cancer, 2021, 147: 154-160. doi: 10.1016/j.ejca.2021.01.033